NEWS
LATEST
FULL LIST
-
Trestle Bio Announces Research Collaboration with Humacyte
Trestle Biotherapeutics, Inc. today announced a research collaboration with Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company focused on developing universally implantable, bioengineered human tissue at commercial scale. Trestle Bio is a preclinical-stage company working on bioengineered kidney tissues for patients with end stage renal disease (ESRD). The collaboration will investigate potential technological synergies…
-
Xenotransplantation Advances: United Therapuetics and eGensis Companies to Watch
In a significant development for the field of xenotransplantation, two biotech companies have recently received critical regulatory approvals that could reshape the future of organ transplantation. Following early clinical successes and notable setbacks, industry leaders are now advancing clinical trials aimed at addressing the chronic shortage of human organs for transplant. The concept of xenotransplantation…
-
ARMI BioFabUSA A Catalyst for Regenerative Medicine
Bringing Biofabrication Companies Together The Advanced Regenerative Manufacturing Institute (ARMI) is leading the charge in revolutionizing the bioeconomy of the United States. As a member-based nonprofit, ARMI operates through its flagship initiative, BioFabUSA, which fosters collaboration among more than 200 partners, including corporations, academic institutions, and nonprofits. The goal: to develop scalable, consistent, and cost-effective…
-
Tissue Therapeutics: The Curative Potential of Combining Cells & Biomaterials
Introduction: Defining Tissue Therapeutics and Tissue Engineering Tissue therapeutics represents a convergence of cell therapy and biomaterials, offering advanced solutions for unmet clinical needs such as organ and tissue repair. Traditional biologics and gene therapies often fall short in providing the structural and functional support necessary for full tissue restoration. Tissue engineering is now making…
-
EU-Funded micro2MACRO Project Aims to Push Cartilage Tissue Regeneration with Bioprinting
Teltow, February 5, 2025 – A new European initiative is set to push the boundaries of tissue regeneration and bioprinting. The micro2MACRO (m2M) project, launched in December 2024, is an EU-funded effort that aims to develop a cutting-edge bioprinting platform capable of generating personalized tissue grafts for medical applications. The project brings together leading academic…
-
Auxilium Biotechnologies Achieves Bioprinting Milestone Aboard the ISS
Auxilium Biotechnologies successfully deployed its 3D bioprinter aboard the International Space Station (ISS). This achievement marks the an instance of implantable medical devices being printed in space, paving further way for advanced medical solutions both on Earth and in future space missions. Printing Medical Devices in Microgravity Auxilium Biotechnologies has successfully 3D bioprinted perfusable vasculature,…
-
United Therapeutics Breaks New Ground with FDA-Cleared Xenotransplantation Trial
The field of organ transplantation is on the cusp of a advancement, with United Therapeutics (NASDAQ: UTHR) achieving a new milestone in xenotransplantation. The U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for its UKidney™ clinical trial, marking the first-ever human trial of a xenokidney designed for potential…
-
Handheld Bioprinting with Kombucha-Based Bioink
The world of bioprinting is evolving rapidly, and a recent study published in the International Journal of Biological Macromolecules from Dr. Insup Noh Lab at Seoul Tech introduces a novel approach that could revolutionize the field: a handheld bioprinting system using kombucha-derived nanocellulose bioink. This innovative method offers promise for regenerating irregular and multilayered tissue defects…
-
Time Code: Improved Printing Code for 3D Bioprinting
Introduction The field of bioprinting has made strides in recent years. However, despite advances in multifunctional 3D printheads, the standard G-Code used for print path execution presents a significant limitation: it forces interruptions in the print process whenever auxiliary controls, such as material switching or UV curing, are required. This leads to defects, reduced precision,…
-
MEDELLAPRO®: Endotoxin-Controlled Bioprinting Materials
The bioprinting industry is advancing, with new materials playing a critical role in pushing the boundaries of regenerative medicine, tissue engineering, and biomedical innovation. One of the latest breakthroughs comes from GELITA, which has introduced MEDELLAPRO®, an endotoxin-controlled gelatin designed specifically for 3D bioprinting, cell culturing, and medical implants. This high-purity biomaterial offers safety, biocompatibility,…
Subscribe
Enter your email below to receive updates.
The Business of Biofabrication 